LU91206I2 - Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel) - Google Patents

Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel)

Info

Publication number
LU91206I2
LU91206I2 LU91206C LU91206C LU91206I2 LU 91206 I2 LU91206 I2 LU 91206I2 LU 91206 C LU91206 C LU 91206C LU 91206 C LU91206 C LU 91206C LU 91206 I2 LU91206 I2 LU 91206I2
Authority
LU
Luxembourg
Prior art keywords
ceftiofur
free acid
naxcel
pharmaceutically acceptable
crystalline free
Prior art date
Application number
LU91206C
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of LU91206I2 publication Critical patent/LU91206I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
LU91206C 1993-03-12 2005-11-16 Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel) LU91206I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3329193A 1993-03-12 1993-03-12
PCT/US1994/001862 WO1994020505A1 (fr) 1993-03-12 1994-03-07 Acide libre cristallin de ceftiofur_______________________

Publications (1)

Publication Number Publication Date
LU91206I2 true LU91206I2 (fr) 2006-05-30

Family

ID=21869579

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91206C LU91206I2 (fr) 1993-03-12 2005-11-16 Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel)

Country Status (31)

Country Link
US (1) US5721359A (fr)
EP (1) EP0690864B1 (fr)
JP (1) JP3852946B2 (fr)
KR (1) KR100296810B1 (fr)
CN (1) CN1055090C (fr)
AT (1) ATE202109T1 (fr)
AU (1) AU694419B2 (fr)
BR (1) BR1101034A (fr)
CA (1) CA2155322C (fr)
CZ (1) CZ289332B6 (fr)
DE (2) DE122005000055I2 (fr)
DK (1) DK0690864T3 (fr)
ES (1) ES2157254T3 (fr)
FI (1) FI120307B (fr)
FR (1) FR05C0045I2 (fr)
GR (1) GR3036514T3 (fr)
HU (1) HU222244B1 (fr)
IL (1) IL108910A (fr)
LU (1) LU91206I2 (fr)
LV (1) LV12889B (fr)
NL (1) NL300208I2 (fr)
NO (2) NO313199B1 (fr)
NZ (1) NZ263002A (fr)
PL (1) PL184611B1 (fr)
PT (1) PT690864E (fr)
RU (1) RU2136685C1 (fr)
SI (1) SI0690864T1 (fr)
SK (1) SK283674B6 (fr)
TW (1) TW267170B (fr)
WO (1) WO1994020505A1 (fr)
ZA (1) ZA941586B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal
US7829100B2 (en) * 2000-09-12 2010-11-09 Teagarden Dirk L Pharmaceutical composition having modified carrier
NZ524694A (en) * 2000-09-12 2005-05-27 Upjohn Co Pharmaceutical composition having modified carrier
KR100423895B1 (ko) * 2001-02-19 2004-03-24 주식회사 엘지생명과학 셉티오퍼 하이드로클로라이드의 현탁제 조성물
MXPA04000294A (es) * 2001-07-10 2004-05-04 Pharmacia & Upjhon Company Tiacin oxazolidinonas cristalinas.
CA2455050C (fr) 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Cristaux comprenant un sel d'acide malique de n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide, procedes de preparation associes et compositions correspondantes
US20030181398A1 (en) 2002-03-21 2003-09-25 Brown Scott A. Method of administering an injectable antibiotic to an animal
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
US20040115822A1 (en) * 2002-09-12 2004-06-17 Schapaugh Randal Lee Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
US20040115837A1 (en) * 2002-11-27 2004-06-17 Schapaugh Randal Lee Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
ES2329244T3 (es) * 2003-03-27 2009-11-24 Basilea Pharmaceutica Ag Cefalosporina en forma cristalina.
US8039482B2 (en) 2004-03-25 2011-10-18 Astellas Pharma Inc. Composition of solifenacin or salt thereof for use in solid formulation
US7815939B2 (en) 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
BRPI0617561A2 (pt) * 2005-10-12 2011-08-23 Orchid Chemicals & Pharm Ltd sal de sódio cristalino antibiótico de cefalosporina
US8470809B2 (en) * 2005-10-12 2013-06-25 Orchid Chemicals & Pharmaceuticals Limited Crystalline sodium salt of cephalosporin antibiotic
CN101835750B (zh) 2007-08-22 2013-07-17 阿斯利康(瑞典)有限公司 环丙基酰胺衍生物
EP2303026B1 (fr) 2008-06-17 2020-09-09 Brigham Young University Procédés de diagnostic, de détection, de tri et d'imagerie de stéroïdes cationiques antimicrobiens
WO2010020871A2 (fr) * 2008-08-22 2010-02-25 Orchid Chemicals & Pharmaceuticals Limited Sel de sodium cristallin de l'antibiotique céphalosporine
CA2743551C (fr) * 2008-11-19 2017-08-15 Merial Limited Formulations comprenant du ceftiofur et du ketoprofene ou du ceftiofur et de l'alcool benzylique
SG172926A1 (en) * 2009-01-30 2011-08-29 Glaxosmithkline Llc Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
BR112012020780A2 (pt) * 2010-02-18 2016-05-03 Astrazeneca Ab forma sólida, composição farmacêutica, e, uso de uma forma sólida.
BR112012020629A2 (pt) 2010-02-18 2018-06-19 Astrazeneca Ab forma cristalina, e, método para a terapia de um distúrbio
CA2834999A1 (fr) * 2011-05-02 2012-11-08 Zoetis Llc Nouvelles cephalosporines utiles en tant qu'agents antibacteriens
CN104039369B (zh) 2011-07-20 2017-06-16 布莱阿姆青年大学 疏水性塞拉集宁化合物和包含该化合物的装置
EP2760454B1 (fr) 2011-09-13 2018-08-29 Brigham Young University Produits pour la guérison de plaies tissulaires
US9603859B2 (en) 2011-09-13 2017-03-28 Brigham Young University Methods and products for increasing the rate of healing of tissue wounds
US9694019B2 (en) 2011-09-13 2017-07-04 Brigham Young University Compositions and methods for treating bone diseases and broken bones
CN104080459B (zh) 2011-09-13 2018-07-03 布莱阿姆青年大学 用于治疗骨疾病和断骨的组合物
CA2859325A1 (fr) 2011-12-21 2013-07-25 Brigham Young University Compositions de soin orales
CN102584855B (zh) * 2012-02-16 2014-06-25 青岛科技大学 一种改进的头孢噻呋的制备方法
US9533063B1 (en) 2012-03-01 2017-01-03 Brigham Young University Aerosols incorporating ceragenin compounds and methods of use thereof
US10039285B2 (en) 2012-05-02 2018-08-07 Brigham Young University Ceragenin particulate materials and methods for making same
BR112015008804A2 (pt) 2012-10-17 2017-07-04 Univ Brigham Young tratamento e prevenção de mastite
WO2014087972A1 (fr) * 2012-12-03 2014-06-12 株式会社カネカ Dérivé de la coenzyme q10 sous sa forme réduite et procédé de production associé
WO2014107740A2 (fr) 2013-01-07 2014-07-10 Brigham Young University Méthodes d'inhibition de la prolifération cellulaire et de traitement de certaines maladies
US10568893B2 (en) 2013-03-15 2020-02-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
BR112015023747B1 (pt) 2013-03-15 2023-04-18 Brigham Young University Uso de um composto antimicrobiano catiônico esteroide (csa) para a preparação de uma composição para tratar, reduzir, ou prevenir inflamação aguda ou crônica e/ou dor aguda ou crônica associada com uma doença ou um sintoma de doença
US11524015B2 (en) 2013-03-15 2022-12-13 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
RU2546675C2 (ru) * 2013-04-11 2015-04-10 Федеральное казённое предприятие "Государственный научно-исследовательский институт химических продуктов" (ФКП "ГосНИИХП") Способ определения степени кристалличности составов на основе дифениламина
US9387215B2 (en) 2013-04-22 2016-07-12 Brigham Young University Animal feed including cationic cholesterol additive and related methods
EP3042893B1 (fr) * 2013-09-05 2018-10-31 Mitsubishi Tanabe Pharma Corporation Nouveau composé arylalkylamine cristallin et son procédé de production
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
CA2844321C (fr) 2014-02-27 2021-03-16 Brigham Young University Composes antimicrobiens steroides cationiques
US10220045B2 (en) 2014-03-13 2019-03-05 Brigham Young University Compositions and methods for forming stabilized compositions with reduced CSA agglomeration
US9867836B2 (en) 2014-03-13 2018-01-16 Brigham Young University Lavage and/or infusion using CSA compounds for increasing fertility in a mammal
US9931350B2 (en) 2014-03-14 2018-04-03 Brigham Young University Anti-infective and osteogenic compositions and methods of use
US9686966B2 (en) 2014-04-30 2017-06-27 Brigham Young University Methods and apparatus for cleaning or disinfecting a water delivery system
US10441595B2 (en) 2014-06-26 2019-10-15 Brigham Young University Methods for treating fungal infections
US10238665B2 (en) 2014-06-26 2019-03-26 Brigham Young University Methods for treating fungal infections
US10227376B2 (en) 2014-08-22 2019-03-12 Brigham Young University Radiolabeled cationic steroid antimicrobials and diagnostic methods
US10155788B2 (en) 2014-10-07 2018-12-18 Brigham Young University Cationic steroidal antimicrobial prodrug compositions and uses thereof
MX2017005120A (es) * 2014-10-21 2018-02-12 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[-2-(dimetilfosforil) fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il] pirimidin-2,4-diamina.
US10370403B2 (en) 2015-04-22 2019-08-06 Brigham Young University Methods for the synthesis of ceragenins
US9527883B2 (en) 2015-04-22 2016-12-27 Brigham Young University Methods for the synthesis of ceragenins
KR101753842B1 (ko) * 2015-05-12 2017-07-04 한국화학연구원 불화퀴놀론계 항생제를 담지한 서방형 제제 및 이의 제조방법
US9434759B1 (en) 2015-05-18 2016-09-06 Brigham Young University Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds
CN106543203B (zh) * 2015-09-18 2019-07-02 瑞普(天津)生物药业有限公司 一种长效头孢噻呋自由酸晶体的制备方法
CA3011323A1 (fr) * 2016-01-22 2017-07-27 Sandoz Ag Bis-chlorhydrate d'eravacycline cristalline
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
KR101898282B1 (ko) * 2016-05-24 2018-09-13 주식회사 고려비엔피 항생제의 서방형 수의학적 조성물 및 이의 제조방법
EP3481820B1 (fr) 2016-07-07 2023-10-18 Cyclerion Therapeutics, Inc. Formes solides d'un stimulateur de la gcs
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
US11186556B1 (en) * 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
TW202233625A (zh) * 2020-11-18 2022-09-01 美商傳達治療有限公司 Fgfr抑制劑及其製造及使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1207933B (de) * 1962-12-26 1965-12-30 American Home Prod Verfahren zur Herstellung von kristallwasser-freiem D-alpha-Aminobenzylpenicillin
US3489752A (en) * 1967-09-05 1970-01-13 Bristol Myers Co 7-amino-cephalosporanic and decephalosporanic acid derivatives
DK154939C (da) * 1974-12-19 1989-06-12 Takeda Chemical Industries Ltd Analogifremgangsmaade til fremstilling af thiazolylacetamido-cephemforbindelser eller farmaceutisk acceptable salte eller estere deraf
DE2760123C2 (de) * 1976-01-23 1986-04-30 Roussel-Uclaf, Paris 7-Aminothiazolyl-syn-oxyiminoacetamidocephalosporansäuren, ihre Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
GB1532682A (en) * 1976-04-27 1978-11-22 Bristol Myers Co Process for the preparation of cephadroxil
FR2479229B1 (fr) * 1980-03-26 1986-01-17 Clin Midy Nouveaux derives des cephalosporines, leur procede de preparation et les medicaments utilisables comme antibiotiques qui contiennent lesdits derives
IL63968A (en) * 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4400503A (en) * 1981-10-30 1983-08-23 Eli Lilly And Company Purification of syn-7-[[(2-amino-4-thiazolyl)(methoxyimino) acetyl]amino]-3-methyl-3-cephem-4-carboxylic acid
DE3313818A1 (de) * 1983-04-16 1984-10-18 Hoechst Ag, 6230 Frankfurt Neue kristallmodifikation von ceftazidim
KR890002631B1 (ko) * 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IT1181672B (it) * 1984-10-25 1987-09-30 Upjohn Co Cefalosporina alogenidrato cristallino
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
US4937330A (en) * 1985-08-12 1990-06-26 The Upjohn Company Conversion of cephalosporin hydrohalide salt to alkali metal salt
GB8608962D0 (en) * 1986-04-12 1986-05-14 Beecham Group Plc Beta-lactam antibiotics
IT1214587B (it) * 1986-12-23 1990-01-18 Giovanni Bonfanti Metodo per la produzione diprodotti cristallini puri.
ATE76874T1 (de) * 1987-02-02 1992-06-15 Lilly Co Eli Verfahren zur herstellung von ceftazidimepentahydrat.
DE3869135D1 (de) * 1987-07-29 1992-04-16 Upjohn Co Kontrollierte freisetzung von antibiotika-salzen aus einem implantat.
AU617377B2 (en) * 1987-11-10 1991-11-28 Pharmacia & Upjohn Company Cephalosporin antibiotics
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes

Also Published As

Publication number Publication date
ATE202109T1 (de) 2001-06-15
PL184611B1 (pl) 2002-11-29
CA2155322A1 (fr) 1994-09-15
DE122005000055I1 (de) 2006-02-23
NO953564D0 (no) 1995-09-11
US5721359A (en) 1998-02-24
FR05C0045I1 (fr) 2006-01-06
EP0690864B1 (fr) 2001-06-13
NL300208I1 (nl) 2006-02-01
CZ289332B6 (cs) 2002-01-16
KR100296810B1 (ko) 2001-10-24
NO313199B1 (no) 2002-08-26
TW267170B (fr) 1996-01-01
JPH08507519A (ja) 1996-08-13
IL108910A0 (en) 1994-06-24
DK0690864T3 (da) 2001-09-17
NO2005025I2 (no) 2010-11-22
ES2157254T3 (es) 2001-08-16
LV12889B (lv) 2002-12-20
FI120307B (fi) 2009-09-15
IL108910A (en) 1999-10-28
CN1119016A (zh) 1996-03-20
DE122005000055I2 (de) 2008-06-05
NO953564L (no) 1995-11-07
ZA941586B (en) 1995-09-07
SK283674B6 (sk) 2003-11-04
AU694419B2 (en) 1998-07-23
SI0690864T1 (en) 2001-10-31
FI954250A (fi) 1995-09-11
FI954250A0 (fi) 1995-09-11
PT690864E (pt) 2001-11-30
HU9501960D0 (en) 1995-09-28
CA2155322C (fr) 2000-02-29
FR05C0045I2 (fr) 2007-08-03
NL300208I2 (nl) 2006-05-01
PL310556A1 (en) 1995-12-27
HUT73781A (en) 1996-09-30
NZ263002A (en) 1996-12-20
JP3852946B2 (ja) 2006-12-06
WO1994020505A1 (fr) 1994-09-15
BR1101034A (pt) 2002-04-30
GR3036514T3 (en) 2001-12-31
CN1055090C (zh) 2000-08-02
SK111495A3 (en) 1995-12-06
DE69427469D1 (en) 2001-07-19
HU222244B1 (hu) 2003-05-28
DE69427469T2 (de) 2001-10-31
NO2005025I1 (no) 2005-12-05
EP0690864A1 (fr) 1996-01-10
CZ9502290A3 (cs) 2001-08-15
RU2136685C1 (ru) 1999-09-10
AU6351094A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
LU91206I2 (fr) Ceftiofur sous forme d'acide libre cristallin et ses dérivés pharmaceutiquement acceptables (naxcel)
IL124537A0 (en) Naphthyl-substituted benzimidazole derivatives and pharmaceutical compositions containing the same
IL108520A0 (en) Imidazopyridine derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them
TW252979B (fr)
HRP950437A2 (en) N-substituted azabicycloheptane derivatives, their production and use
IL107232A0 (en) 19, 11-bridged 4-estrene derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
DE69318715D1 (de) Pharmakologisch aktive alpha-(tertiär-aminoethyl)-phenylmethanol-derivate
GR3030731T3 (en) Anthracycline disaccharides, process for their preparation, and pharmaceutical compositions containing them
AU7000994A (en) Phosphosuccinic acid derivatives and their use as medicaments